Investor Relations

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Apr 30, 2024
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
NEW YORK , April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other
Mar 21, 2024
MiNK Reports Fourth Quarter and Year-End 2023 Results
Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development of TCR-based therapies Published clinical data in Nature Communications and Oncogene demonstrating
Corporate Presentation

SEC Filings

Form Description Filing date View
SC 13G

A statement of beneficial ownership of common stock by certain persons

 View HTML
0001193125-22-041640.pdf
0001193125-22-041640.rtf
0001193125-22-041640.xls
S-1/A

Amended Registration statement for face-amount certificate companies

 View HTML
0001193125-21-296215.pdf
0001193125-21-296215.rtf
0001193125-21-296215.xls
4/A

Amendment to a previously filed 4

 View HTML
0000950170-23-024556.pdf
0000950170-23-024556.rtf
0000950170-23-024556.xls
4/A

Amendment to a previously filed 4

 View HTML
0000950170-23-024567.pdf
0000950170-23-024567.rtf
0000950170-23-024567.xls

Data provided by Kaleidoscope.